Teladoc Health Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
TDOC$8.98+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,298,327 | $1,123,675 |
| Accounts receivable, net of allowance for doubtful accounts of $5,134 and $4,240 at December 31, 2024 and December 31, 2023, respectively | 214,146 | 217,423 |
| Inventories | 38,138 | 29,513 |
| Prepaid expenses and other current assets | 113,296 | 118,437 |
| Total current assets | 1,663,907 | 1,489,048 |
| Property and equipment, net | 29,487 | 32,032 |
| Goodwill | 283,190 | 1,073,190 |
| Intangible assets, net | 1,431,360 | 1,677,781 |
| Operating lease—right-of-use assets | 27,092 | 40,060 |
| Other assets | 81,488 | 80,258 |
| Total assets | $3,516,524 | $4,392,369 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $33,130 | $43,637 |
| Accrued expenses and other current liabilities | 202,157 | 178,634 |
| Accrued compensation | 76,229 | 102,686 |
| Deferred revenue—current | 79,296 | 95,659 |
| Convertible senior notes, net—current | 550,723 | — |
| Total current liabilities | 941,535 | 420,616 |
| Other liabilities | 720 | 1,080 |
| Operating lease liabilities, net of current portion | 32,135 | 42,837 |
| Deferred revenue, net of current portion | 9,786 | 13,623 |
| Deferred taxes, net | 49,851 | 49,452 |
| Convertible senior notes, net—non-current | 991,418 | 1,538,688 |
| Total liabilities | 2,025,445 | 2,066,296 |
| Commitments and contingencies (Note 17) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized; 173,405,016 shares and 166,658,253 shares issued and outstanding as of December 31, 2024 and December 31, 2023 respectively | 173 | 167 |
| Additional paid-in capital | 17,759,194 | 17,591,551 |
| Accumulated deficit | (16,229,900) | (15,228,655) |
| Accumulated other comprehensive loss | (38,388) | (36,990) |
| Total stockholders’ equity | 1,491,079 | 2,326,073 |
| Total liabilities and stockholders’ equity | $3,516,524 | $4,392,369 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.